Sugi Predict

Sugi Predict / Compounds / SCHEMBL3347281

SCHEMBL3347281

SCHEMBL3347281

CCOc1ccc(-c2nc(Nc3cc(C(=O)NC4CC4)ccc3C)sc2C(=O)NCc2ccccc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.49
▸ MAPK14 Q16539 6/20 0.47
▸ MEN1 O00255 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ MAPK11 Q15759 4/20 0.44
▸ TP53 P04637 2/20 0.44
▸ LMNA P02545 1/20 0.43
▸ POLB P06746 1/20 0.43
▸ RXFP1 Q9HBX9 1/20 0.43
▸ DGAT1 O75907 1/20 0.43
▸ DHODH Q02127 1/20 0.41
▸ ADORA3 P0DMS8 1/20 0.41
▸ ROCK2 O75116 1/20 0.41
▸ ROCK1 Q13464 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3346424 0.94 MAPK14 (0.46) MAPTMAPK14MAPK11TP53LMNA
SCHEMBL3345794 0.93 MAPK14 (0.53) MAPTMAPK14RAB9AMAPK11TP53
SCHEMBL3345756 0.93 MAPK14 (0.48) MAPTMAPK14RAB9AMAPK11TP53
SCHEMBL3319396 0.92 DHODH (0.47) MAPTMAPK14MEN1KMT2AMAPK11
SCHEMBL27635999 0.91 MAPK14 (0.50) MAPTMAPK14KMT2AMAPK11TP53
SCHEMBL3313848 0.91 MAPK14 (0.47) MAPTMAPK14MAPK11TP53LMNA
SCHEMBL3346606 0.91 MAPT (0.49) MAPTMAPK14MEN1KMT2AMAPK11
SCHEMBL3345188 0.90 MAPK14 (0.49) MAPTMAPK14MAPK11TP53LMNA
SCHEMBL3345525 0.90 MAPK14 (0.49) MAPTMAPK14MAPK11TP53LMNA
SCHEMBL3351894 0.89 MAPK14 (0.52) MAPTMAPK14MAPK11TP53LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7652044-B2 P-38 inhibitors NOVARTIS A.G. (CH) 2010-01-26 — — US claimed
US-20100004298-A1 P-38 INHIBITORS DONG QING 2010-01-07 — — US claimed
EP-1635824-B1 5-MEMBERED HETEROCYCLE-BASED P-38 INHIBITORS NOVARTIS AG (CH) 2009-08-19 — — EP claimed
EP-1635824-A2 5-MEMBERED HETEROCYCLE-BASED P-38 INHIBITORS Novartis AG (CH) 2006-03-22 — — EP claimed
WO-2005000298-A2 5-MEMBERED HETEROCYCLE-BASED P-38 INHIBITORS NOVARTIS AG (CH) 2005-01-06 — — WO claimed
US-20040254236-A1 P-38 inhibitors NOVARTIS AG (CH) 2004-12-16 — — US claimed
US-7652044-B2 P-38 inhibitors NOVARTIS A.G. (CH) 2010-01-26 — — US disclosed
US-7652044-B2 P-38 inhibitors NOVARTIS A.G. (CH) 2010-01-26 — — US disclosed
US-7652044-B2 P-38 inhibitors NOVARTIS A.G. (CH) 2010-01-26 — — US disclosed
US-20100004298-A1 P-38 INHIBITORS DONG QING 2010-01-07 — — US disclosed
US-20100004298-A1 P-38 INHIBITORS DONG QING 2010-01-07 — — US disclosed
US-20100004298-A1 P-38 INHIBITORS DONG QING 2010-01-07 — — US disclosed
EP-1635824-B1 5-MEMBERED HETEROCYCLE-BASED P-38 INHIBITORS NOVARTIS AG (CH) 2009-08-19 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004298-A1 P-38 INHIBITORS MAPK8, MAPK1, MAP3K8 MAPT 725/4885MAPK14 21/4885MEN1 4323/4885
US-20040254236-A1 P-38 inhibitors MAPK8, MAP3K8, MAPK1 MAPT 817/4885MAPK14 12/4885MEN1 4051/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.